The site's own record of the public posts it publishes, kept so that they can still be read and cited if they are deleted. The words are the account's, exactly as collected from X, except that a mention of an account that is not public is replaced by a neutral label.
From our Spotlight:
"the rate of transgender self-identification among undergraduates in our data is higher than that reported from CDC survey data for a comparable age group (18–24-year-olds) in the same year (3.7%–3.9% in 2022 in our data vs 2.8% in the CDC survey data). Several factors likely contribute to this difference. Our data are unweighted, and about 70% of respondents are female, a group with higher rates of transgender identification. In addition, our data reflect college students, whereas the CDC survey data are nationally representative of all young adults. It is likely that the rate of transgender identification is higher among college students than among young adults in general."
There are conflicting reports regarding current trends in transgender identification among youth. Our updated analysis with data through the end of 2025 shows yet another increase in trans identification, with 9% of females and 5% of males on undergraduate campuses reporting a sex-incongruent gender identity—an all-time high. Our preliminary analysis of the spring 2026 data suggests the trend is continuing. /4
As of 2025, 9% of females and 5% of males on U.S. college campuses have a sex-incongruent identity. These estimates are derived by the National College Health Assessment (NCHA) based on students' answers to questions about sex and gender identity. /2
https://segm.org/US-college-trans-id-fall-2025
🚨 Claims that youth trans identities have "plummeted" are greatly exaggerated. SEGM's new analysis shows that trans identification on U.S. college campuses reached an all-time high in 2025—a 3,600% increase since 2000. The trend is female-dominated.
Read the Spotlight ⬇️ /1
The fact that the result of hormonal and surgical interventions for gender dysphoria can prove to be "psychologically debilitating" for the patients has long been acknowledged. This is, in part, the reason why the early guidelines in transgender medicine set out strict eligibility and readiness criteria and recommended careful and extended mental health assessments.
However, the authors describe how the awareness of the risk of harm of gender transitions, which used to be front and center of clinical decision-making, gave way to the "gender-affirming" paradigm. This paradigm devalued psychological assessments and progressively lowered minimum age requirements, extending medical transition to children and adolescents. /6
Being treated with dignity should not depend on the results of one's brain scan. That said, a new paper found the evidence in a widely cited "transgender brain" study to be unconvincing, citing a small sample and no adjustment for sexual orientation.
https://link.springer.com/article/10.1007/s11186-026-09747-2
Undoubtedly, the signatories of the letter believed they were protecting trans kids from lawmakers they saw as restricting access to lifesaving care. But good intentions cannot justify endorsing flawed science or selective use of evidence. /3
https://hpmmatters.publichealth.gwu.edu/sites/g/files/zaxdzs6671/files/2026-02/CMS%20Medicaid%20and%20CHIP%20Funding%20Restrictions%20for%20GAC_Comment%20Letter_021726.pdf
Leaning on the pro-state-bans Skrmetti ruling, WPATH argues that the states have the right to regulate transgender interventions. While some states exercised their right to ban them—other states likewise have the right to promote transgender interventions for minors, using WPATH as the state-endorsed standard of care. /5
To defend itself against the FTC in the federal court, WPATH leans 𝐟𝐚𝐯𝐨𝐫𝐚𝐛𝐥𝐲 on two Supreme Court rulings that under normal circumstances it decries. One is Skrmetti, which allowed states to ban transgender interventions for minors. The other is the pro-"conversion therapy" Chiles v. Salazar ruling. /4
WPATH now agrees that pediatric transgender medicine is marked by "medical and scientific uncertainty." It represents its SOC-8 recommendations merely as an expression of WPATH's "free speech." Yet for years, WPATH presented its guidelines as an unquestionable medical standard of care. The social and scientific costs of questioning their recommendations were steep and could be career-ending. /2
The author of the publication is a renowned Swedish psychiatrist, Mikael Landén, whose career has been dedicated to transgender medicine. Landén argues that given the current lack of definitional clarity of what it is that is being treated, and the problematic evidence regarding the risk-benefit ratio of the "affirming" medical interventions, gender transitions for youth should not be offered in standard medical practice, following the "first do no harm" principle.
In making a case for the "do no harm" approach, Landén makes the following points: /4
All psychological models agree that adolescent identity is in flux and that identities are co-constructed. There is no reason to believe that these same principles don't apply to adolescent trans identities. What is unique in pediatric gender medicine is that clinicians are tasked with predicting identity development—but no tool for this exists, argues Dr. Anna Hutchinson, at the joint @[private account] -SEGM conference at @[private account] today.
SEGM takes no position on autonomous decisions by competent adults. Its concern is pediatric medical transition, based on independent evidence reviews and normative medical ethics.
Calling that “anti-trans” suggests the scale is already broken. Evidence-based medicine in pediatrics is not “a thumb on the scale.”
As the world awaits the Dutch Health Council's assessment of the Dutch Protocol due to be published tomorrow (June 30th, 2026)—the following publications provide excellent background reading into the concerns raised by researchers and clinicians worldwide dating back to 2022:
1. "Reconsidering informed consent for trans-identified children, adolescents, and young adults" https://www.tandfonline.com/doi/full/10.1080/0092623X.2022.2046221
2. "The myth of “reliable research” in pediatric gender medicine: A critical evaluation of the Dutch studies—and research that has followed" https://www.tandfonline.com/doi/full/10.1080/0092623X.2022.2150346
3. "The Dutch Protocol for Juvenile Transsexuals: Origins and Evidence"
https://www.tandfonline.com/doi/full/10.1080/0092623X.2022.2121238
4. "Three decades of ‘Dutch Protocol’ research has not produced reliable evidence"
https://www.tandfonline.com/doi/full/10.1080/17405629.2026.2680285
5. "The Health Council of the Netherlands and the Regulatory Environment Surrounding Puberty Blockers for Minors"
https://www.njb.nl/media/qrfbgd1l/njb40_de-gezondheidsraad-en-het-reguleringsklimaat-rond-puberteitsremming-bij-minderjarigen.pdf
/end
There is also a marked absence of appropriate patient representation by the patient population most affected by the Dutch Protocol—adolescent females with serious mental health comorbidities. Instead, patient representation is delegated to transgender advocacy organizations. The article notes:
"Patient involvement is essential in the development of
healthcare standards. But the question of who “the patient” is in this context complicates matters. The relevant target group for puberty blockers consists primarily of minors born female
(approximately 10–14 years old), often with comorbidities such as autism, trauma, or depression. Their age makes meaningful participation virtually impossible. Furthermore, this is an intervention whose hormonal, sexual, and reproductive consequences do not manifest until much later.
In practice, the voice of this group is almost entirely
represented by transgender advocacy organizations.
This is a structural bias: these organizations represent the perspective of adult transgender people with an established identity, for whom access to treatment is primarily about autonomy and the rapid removal of barriers. From that perspective, a cautious selection process is paternalistic and frustrating; lowering barriers is therefore a legitimate priority. " /7
The Trevor Project press release quoted the study’s senior author, who was the Trevor Project’s Vice President of Research, stating that the study “critically confirms—for the first time—a causal relationship between anti-transgender laws and heightened suicide risk among transgender and nonbinary young people.”
However, as Cohn et al.'s critique demonstrates, neither the press release’s headline of an “up to 72% increase in suicide attempts” nor any conclusions about any increases in suicidality following restrictive laws are credibly supported by the data. /9
Further, very different laws were all framed as "anti-transgender" and lumped into one category. A law merely calling for a study would have been treated the same as one banning males from female sports, and the same as laws imposing medical restrictions on pediatric transition. That limits the interpretability of every result. /6
🧵Last year, a paper by the @[private account] authors claimed that "anti-transgender" laws cause a 7–72% increase in youth suicide attempts—a figure since cited in media, policy, and litigation. A new critique in @[private account] shows the claim doesn't add up. New SEGM spotlight⬇️/1
Data for these graphs come from the two studies below, focused on the commercially insured population, with graph-based estimates where a study did not report the underlying figures.
*Gray et al., Gender-affirming care for transgender and gender-diverse youth in Oregon, Research Connections, 2026
*Hughes et al., Gender-affirming medications among transgender adolescents in the US, 2018–2022, JAMA Pediatrics, 2025
/end
When Oregon mandated Medicaid coverage for gender reassignment in 2015, it estimated that about 175 patients across all ages would seek gender-related services. The new data on adolescents alone suggest that projection was far too conservative. /3
https://www.npr.org/sections/health-shots/2015/01/10/376154299/in-oregon-medicaid-now-covers-transgender-medical-care
The Trevor Project study’s claim of elevated suicidality in youth following the passage of “anti-transgender” laws has been cited over 100 times, and often in the context of opposition to restrictions on youth transitions. However, as the new commentary convincingly demonstrates, this finding is at a critical risk of bias and not reliable. /4
The peer-reviewed commentary by Cohn et al. identifies major limitations in the original Nature Human Behaviour study. Its headline claim — that “anti-trans” laws caused a 72% rise in suicidality — relied heavily on a few hundred respondents from Idaho, where no laws restricting pediatric transition were in effect during the study period.
The only two potentially relevant laws in Idaho around the study time period were HB 500, which restricted male participation in the female category in school sports, and HB 509, which concerned the recording of sex on birth certificates.
But one of these laws was blocked more than a year before the signal of increased suicidality appeared in the data—and the other never went into effect at all.
/3
Two years ago, a paper in Nature Human Behaviour claimed that “anti-trans” laws, including restrictions on pediatric gender transition, increased suicidality among gender-dysphoric youth. Today, a commentary in the same journal challenges that claim. /2
https://www.nature.com/articles/s41562-026-02467-8